Search results for "vid"

showing 10 items of 14131 documents

De Novo and Inherited Pathogenic Variants in KDM3B Cause Intellectual Disability, Short Stature, and Facial Dysmorphism

2019

Contains fulltext : 202646.pdf (Publisher’s version ) (Open Access) By using exome sequencing and a gene matching approach, we identified de novo and inherited pathogenic variants in KDM3B in 14 unrelated individuals and three affected parents with varying degrees of intellectual disability (ID) or developmental delay (DD) and short stature. The individuals share additional phenotypic features that include feeding difficulties in infancy, joint hypermobility, and characteristic facial features such as a wide mouth, a pointed chin, long ears, and a low columella. Notably, two individuals developed cancer, acute myeloid leukemia and Hodgkin lymphoma, in childhood. KDM3B encodes for a histone …

0301 basic medicineMaleJumonji Domain-Containing Histone DemethylasesDevelopmental DisabilitiesWEAVER SYNDROMEPROTEINHaploinsufficiencyCraniofacial AbnormalitiesHistones0302 clinical medicineIntellectual disabilityTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]Missense mutationDEMETHYLASE KDM3BExomeChildGenetics (clinical)Exome sequencingGeneticsRUBINSTEIN-TAYBI SYNDROMEMetabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6]Phenotype030220 oncology & carcinogenesisFemalemedicine.symptomHaploinsufficiencyRare cancers Radboud Institute for Health Sciences [Radboudumc 9]Joint hypermobilityGENETICSJMJD1CMutation MissenseDwarfismBiologyShort statureKdm3b ; Cancer Predisposition ; Developmental Delay ; Facial Recognition ; Intellectual Disability ; Leukemia ; Lymphoma ; Short Stature03 medical and health sciencesReportIntellectual DisabilitymedicineHumansMYELOID-LEUKEMIAGenetic Association StudiesGerm-Line MutationWeaver syndromeNeurodevelopmental disorders Donders Center for Medical Neuroscience [Radboudumc 7]Rubinstein–Taybi syndromeMUTATIONSDELETIONGenetic Variationmedicine.diseaseBody HeightMusculoskeletal AbnormalitiesINDIVIDUALS030104 developmental biologyFaceNanomedicine Radboud Institute for Molecular Life Sciences [Radboudumc 19]American Journal of Human Genetics
researchProduct

Effectiveness of the physical activity intervention program in the PREDIMED-Plus study: a randomized controlled trial

2018

[Background] The development and implementation of effective physical activity (PA) intervention programs is challenging, particularly in older adults. After the first year of the intervention program used in the ongoing PREvención con DIeta MEDiterránea (PREDIMED)-Plus trial, we assessed the initial effectiveness of the PA component.

0301 basic medicineMaleMediterranean diethumanosrestricción calóricaMyocardial InfarctionMedicine (miscellaneous)physical activitycardiovascular-diseaseejercicio físicoDiet MediterraneanPersones granslaw.inventionmissing data0302 clinical medicineClinical trialsRandomized controlled trialpreventionlawSurveys and QuestionnairesClinical endpoint030212 general & internal medicineolder-adultsStrokeGeneralized estimating equationlcsh:RC620-627mediana edadolder adultsBody mass index2. Zero hungerancianoNutrition and Dieteticssobrepesodietaresultado del tratamientolcsh:Public aspects of medicinehealthMiddle Agedwaist circumference3. Good healthlcsh:Nutritional diseases. Deficiency diseasesTreatment Outcomeestilo de vidaOlder adultsWaist circumferenceFemalewomenpérdida de pesometaanalysisRandomized control trialmedicine.medical_specialtyWaistPes corporalPhysical Therapy Sports Therapy and RehabilitationExercicibody mass indexClinical nutrition03 medical and health sciencesWeight LossmedicineHumansIntervention programObesityLife StyleobesidadExerciseinfarto de miocardioAgedCaloric Restriction030109 nutrition & dieteticsperímetro abdominalbusiness.industrybehaviorPhysical activityResearchíndice de masa corporallcsh:RA1-1270OverweightBody weightmedicine.diseaserandomized control trialDiettamaño de la muestraintervention programSample SizePhysical therapyOlder peoplebusinessBody mass indexAssaigs clínicsInternational Journal of Behavioral Nutrition and Physical Activity
researchProduct

Short‐term neuropsychiatric outcomes and quality of life in COVID‐19 survivors

2021

BACKGROUND: The general medical impacts of coronavirus (COVID-19) are increasingly appreciated. However, its impact on neurocognitive, psychiatric health and quality of life (QoL) in survivors after the acute phase is poorly understood. We aimed to evaluate neurocognitive function, psychiatric symptoms, and QoL in COVID-19 survivors shortly after hospital discharge. METHODS: This was a cross-sectional analysis of a prospective study of hospitalised COVID-19 survivors followed-up for 2 months after discharge. A battery of standardised instruments evaluating neurocognitive function, psychiatric morbidity, and QoL (mental and physical components) was administered by telephone. RESULTS: Of the …

0301 basic medicineMalePediatrics030204 cardiovascular system & hematologyAnxietySevere Acute Respiratory SyndromeStress Disorders Post-Traumatic0302 clinical medicineCognitionQuality of lifeOutcome Assessment Health CareMedicineVerbal fluency testProspective StudiesSurvivorsProspective cohort studyLetter to the EditorDepression (differential diagnoses)Aged 80 and overPsychiatryDepressionMiddle AgedsequelaehumanitiesMemory Short-TermneurocognitiveAnxietyFemaleOriginal Articlemedicine.symptomAdultmedicine.medical_specialtypsychiatric morbidity03 medical and health sciencesYoung AdultSex FactorsCOVID‐19Internal MedicineHumansAgedMemory Disordersbusiness.industryWorking memorySARS-CoV-2COVID-19Original Articles030104 developmental biologyCross-Sectional Studiesquality of lifeDeliriumbusinessCognition DisordersNeurocognitiveCOVID-19 neurocognitive psychiatric morbidity quality of life sequelaeJournal of Internal Medicine
researchProduct

Proper assignation of reactivation in a COVID-19 recurrence initially interpreted as a reinfection

2021

A 77-year-old-male (Case R) who had had a previous diagnosis of mild COVID-19 episode, was hospitalized 35 days later. On Day 23 post-admission, he developed a second COVID-19 episode, now severe, and finally died. Initially, Case R COVID-19 recurrence was interpreted as a reinfection due to the exposure to a SARS-CoV-2 RT-PCR-positive room-mate. However, whole-genome-sequencing indicated that case R recurrence corresponded to a reactivation of the strain involved in his first episode. Case R reactivation had major consequences, leading to a more severe episode, and causing a subsequent transmission to another two hospitalized patients, one of them with fatal outcome.

0301 basic medicineMalePediatricsmedicine.medical_specialty2019-20 coronavirus outbreakFatal outcomeCoronavirus disease 2019 (COVID-19)Hospitalized patientsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Antibodies Viral03 medical and health sciences0302 clinical medicineNosocomial transmissionRecurrencemedicineImmunology and AllergyHumans030212 general & internal medicineAgedFirst episodeWhole Genome Sequencingbusiness.industrySARS-CoV-2Nosocomial transmissionBrief ReportCOVID-19Reactivation030104 developmental biologyInfectious DiseasesAcademicSubjects/MED00290ReinfectionbusinessWGS
researchProduct

RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis…

2020

Abstract Objective The hypothesis that been set forward that use of Renin Angiotensin Aldosterone System (RAAS) inhibitors is associated with COVID−19 severity. We set-up a multicenter Italian collaboration (CORIST Project, ClinicalTrials.gov ID: NCT04318418 ) to retrospectively investigate the relationship between RAAS inhibitors and COVID−19 in-hospital mortality. We also carried out an updated meta-analysis on the relevant studies. Methods We analyzed 4069 unselected patients with laboratory-confirmed SARS-CoV-2 infection and hospitalized in 34 clinical centers in Italy from February 19, 2020 to May 23, 2020. The primary end-point in a time-to event analysis was in-hospital death, compar…

0301 basic medicineMalePhysiologyMiddle Aged Renin-Angiotensin SystemAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyACE-I; ARB; COVID-19; angiotensin converting enzyme inhibitors; angiotensin receptor blockers; mortality; sartansSeverity of Illness IndexRenin-Angiotensin System0302 clinical medicineangiotensin converting enzyme inhibitorsRisk FactorsACE-I80 and overMedicineHospital MortalitySartanAged 80 and overIncidence (epidemiology)IncidenceHazard ratioAngiotensin Receptor AntagonistMiddle AgedsartansARBHospitalizationAntihypertensive AgentItalyMeta-analysisHypertensionSartansMolecular MedicineFemaleRisk assessmentHumanmedicine.medical_specialtyAngiotensin converting enzyme inhibitors; ACE-I; Angiotensin receptor blockers; ARB; Sartans; COVID-19; MortalityCoronavirus disease 2019 (COVID-19)Risk AssessmentArticleCOVID−1903 medical and health sciencesAngiotensin Receptor AntagonistsMeta-Analysis as TopicInternal medicineSeverity of illnessHumansAngiotensin receptor blockerMortalityAntihypertensive AgentsAgedPharmacologyACE-I; ARB; Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; COVID−19; Mortality; Sartans; Aged; Aged 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; COVID-19; Female; Hospitalization; Humans; Hypertension; Incidence; Italy; Male; Meta-Analysis as Topic; Middle Aged; Renin-Angiotensin System; Risk Assessment; Risk Factors; Severity of Illness Index; Hospital Mortalitybusiness.industryRisk FactorCOVID-19Angiotensin-Converting Enzyme InhibitorAngiotensin receptor blockersmortalityConfidence intervalangiotensin receptor blockersAngiotensin converting enzyme inhibitors030104 developmental biologyACE-I; ARB; COVID-19 angiotensin converting enzyme inhibitors angiotensin receptor blockers mortality sartansObservational studyAngiotensin converting enzyme inhibitorbusiness
researchProduct

Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres.

2021

Abstract Objectives To our knowledge no previous study has assessed the performance of a rapid antigen diagnostic immunoassay (RAD) conducted at the point of care (POC). We evaluated the Panbio™ COVID-19 Ag Rapid Test Device for diagnosis of coronavirus 2019 disease (COVID-19) in symptomatic patients (n = 412) attending primary healthcare centres. Methods RAD was performed immediately after sampling following the manufacturer's instructions (reading at 15 min). RT-PCRs were carried out within 24 h of specimen collection. Samples displaying discordant results were processed for culture in Vero E6 cells. Presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in cell cultures…

0301 basic medicineMaleRapid antigen detection test (RAD)medicine.disease_causeAmbulatory Care Facilities0302 clinical medicineNasopharynx030212 general & internal medicineChildAntigens ViralCoronavirusAged 80 and overImmunoassaymedicine.diagnostic_testGeneral MedicineMiddle AgedEarly diagnosisResearch NoteInfectious DiseasesSpecimen collectionRapid antigen testPoint-of-Care TestingCOVID-19 Nucleic Acid TestingChild PreschoolFemaleMicrobiology (medical)Adultmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)AdolescentPoint-of-care testing030106 microbiologySensitivity and SpecificityCOVID-19 Serological Testing03 medical and health sciencesYoung AdultAntigenInternal medicinemedicineHumansPoint of careAgedbusiness.industrySARS-CoV-2COVID-19InfantImmunoassayReagent Kits DiagnosticbusinessPrimary healthcare centreClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
researchProduct

Genetic justification of severe COVID-19 using a rigorous algorithm

2021

Recent studies suggest excessive complement activation in severe coronavirus disease-19 (COVID-19). The latter shares common characteristics with complement-mediated thrombotic microangiopathy (TMA). We hypothesized that genetic susceptibility would be evident in patients with severe COVID-19 (similar to TMA) and associated with disease severity. We analyzed genetic and clinical data from 97 patients hospitalized for COVID-19. Through targeted next-generation-sequencing we found an ADAMTS13 variant in 49 patients, along with two risk factor variants (C3, 21 patients; CFH,34 patients). 31 (32%) patients had a combination of these, which was independently associated with ICU hospitalization (…

0301 basic medicineMaleThrombomodulinSeverity of Illness Index0302 clinical medicineRisk FactorsImmunology and AllergyMedicineComplement ActivationRigorous algorithmmedicine.diagnostic_testHigh-Throughput Nucleotide SequencingComplement C3EculizumabEculizumabMiddle AgedHospitalizationSettore ICAR/09 - Tecnica Delle CostruzioniIntensive Care UnitsFactor HComplement Factor HFemaleAlgorithmsmedicine.drugmedicine.medical_specialtyThrombotic microangiopathyCritical CareImmunologyComplementADAMTS13 Protein03 medical and health sciencesInternal medicineFull Length ArticleSeverity of illnessGenetic predispositionGenetic susceptibilityHumansGenetic Predisposition to DiseaseGenetic TestingRisk factorGenetic testingAgedbusiness.industryThrombotic MicroangiopathiesCOVID-19medicine.diseaseComplement system030104 developmental biologySARS-CoV2business030215 immunologyClinical Immunology (Orlando, Fla.)
researchProduct

Dietary Marine ω-3 Fatty Acids and Incident Sight-Threatening Retinopathy in Middle-Aged and Older Individuals With Type 2 Diabetes Prospective Inves…

2016

IMPORTANCE: Diabetic retinopathy (DR) is a devastating complication of individuals with type 2 diabetes mellitus. The retina is rich in long-chain ω−3 polyunsaturated fatty acids (LCω3PUFAs), which are substrate for oxylipins with anti-inflammatory and antiangiogenic properties. Experimental models support dietary LCω3PUFA protection against DR, but clinical data are lacking. OBJECTIVE: To determine whether LCω3PUFA intake relates to a decreased incidence of sight-threatening DR in individuals with type 2 diabetes older than 55 years. DESIGN, SETTING, AND PARTICIPANTS: In late 2015, we conceived a prospective study within the randomized clinical trial Prevención con Dieta Mediterránea (PRED…

0301 basic medicineMaleTime FactorsMediterranean diet2168-6165Type 2 diabetesDieta mediterrànialaw.inventionRandomized controlled triallawRisk FactorsProspective StudiesProspective cohort studyAged 80 and overBioquímica y tecnologíaDiabetisIncidenceDiabetic retinopathyMiddle AgedType 2 DiabetesBiochemistry and technologyTreatment OutcomeFemalemedicine.medical_specialtyBioquímica i biotecnologiaRisk AssessmentOlder IndividualsArticle03 medical and health sciencesInternal medicineDiabetes mellitusFatty Acids Omega-3medicineHumansAgedDiabetic Retinopathybusiness.industryType 2 Diabetes MellitusPREDIMED studymedicine.diseaseSurgeryOphthalmology030104 developmental biologyDiabetes Mellitus Type 2SeafoodSpainRelative riskDietary SupplementsRetinopatia diabèticabusinessFollow-Up Studies
researchProduct

Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemilu…

2021

medRxiv: https://doi.org/10.1101/2020.09.07.20188151

0301 basic medicineMalevirusesAntibodies ViralImmunoglobulin Glaw.invention0302 clinical medicineMedical microbiologylawMedicine030212 general & internal medicineNeutralizing antibodyImmunoassaychemistry.chemical_classificationmedicine.diagnostic_testbiologyAntibody titerGeneral MedicineMiddle AgedHospitalizationTiterInfectious DiseasesSpike Glycoprotein CoronavirusOriginal ArticleFemaleAntibodyMicrobiology (medical)Adultmedicine.medical_specialtySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030106 microbiologyNeutralizing antibodiesSensitivity and SpecificityVirusCOVID-19 Serological Testing03 medical and health sciencesEnzyme-linked immunosorbent assayNeutralization TestsHumansAgedChemiluminescenceSARS-CoV-2business.industryfungiCOVID-19Antibodies NeutralizingVirologyChemiluminescent immunoassaysKineticsEnzymechemistryImmunoassayImmunoglobulin Gbiology.proteinbusiness
researchProduct

Non-neuronal acetylcholine involved in reproduction in mammals and honeybees.

2017

Bacteria and archaea synthesize acetylcholine (ACh). Thus, it can be postulated that ACh was created by nature roughly three billion years ago. Therefore, the wide expression of ACh in nature (i.e., in bacteria, archaea, unicellular organisms, plants, fungi, non-vertebrates and vertebrates and in the abundance of non-neuronal cells of mammals) is not surprising. The term non-neuronal ACh and non-neuronal cholinergic system have been introduced to describe the auto- and paracrine, that is, local regulatory actions of ACh in cells not innervated by neuronal cholinergic fibers and to communicate among themselves. In this way non-neuronal ACh binds to the nicotinic or muscarinic receptors expre…

0301 basic medicineMammalsInsecticidesNicotineCholinergic FibersBiologyBiochemistryEmbryonic stem cellReceptors MuscarinicAcetylcholineCell biology03 medical and health sciencesCellular and Molecular NeuroscienceParacrine signalling030104 developmental biologyNicotinic agonistCell MovementMuscarinic acetylcholine receptormedicineOviductAnimalsHumansAcetylcholineFunction (biology)medicine.drugJournal of neurochemistry
researchProduct